These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 29157287)

  • 41. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
    O'reilly A; Larkin J
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
    Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
    Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.
    Tsakonas G; De Petris L; Ekman S
    Cancer Treat Rev; 2017 Mar; 54():122-131. PubMed ID: 28254730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma.
    Flynn MJ; Sayed AA; Sharma R; Siddique A; Pinato DJ
    Hepatology; 2019 May; 69(5):2258-2270. PubMed ID: 30382576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature.
    Mamdani H; Wu H; O'Neil BH; Sehdev A
    Discov Med; 2017 May; 23(128):331-336. PubMed ID: 28715649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
    Champiat S; Ileana E; Giaccone G; Besse B; Mountzios G; Eggermont A; Soria JC
    J Thorac Oncol; 2014 Feb; 9(2):144-53. PubMed ID: 24419410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.